Human In Vitro Models of Ischaemic Stroke: A Test Bed for Translation

Translational Stroke Research

Volumn 3, Issue 3, 2012, Pages 306-309

  Antonic, Ana ^a   Sena, Emily S ^a,b   Donnan, Geoffrey A ^a   Howells, David W ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ASTROCYTE; BIOCHEMISTRY; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOLOGY; DISEASE MODEL; DRUG INDUSTRY; DRUG SCREENING; EDITORIAL; EMBRYONIC STEM CELL; EXTRACELLULAR FLUID; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MACROGLIA; MICROFLUIDICS; MUTATION; NEUROBLASTOMA; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REPERFUSION INJURY; SYNAPSE; VASCULAR ENDOTHELIUM; WHITE MATTER;

EID: 84865751349     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0201-x     Document Type: Editorial

References (26)

1. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 Experimental treatments in acute stroke. Am Neurol Assoc. 2006; 59: 467-77.
2. Schulz KF, Altman DG, Moher D, for the CG. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010; 7(3): e1000251. doi: 10. 1371/journal. pmed. 1000251.
3. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007; 30(9): 433-9.
4. Howells DW, Porritt MJ, Rewell SSJ, O'Collins V, Sena ES, van der Worp HB, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab. 2010; 30(8): 1412-31.
5. van der Worp HB, Macleod MR. Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol. 2011; 51(4): 449-50. doi: 10. 1016/j. yjmcc. 2011. 04. 008.
6. Li WH. Molecular evolution. Sunderland: Sinauer; 1997.
7. Ho PW, Reutens DC, Phan TG, Wright PM, Markus R, Indra I, et al. Is white matter involved in patients entered into typical trials of neuroprotection? Stroke. 2005; 36(12): 2742-4.
8. DeFelipe J, Alonso-Nanclares L, Arellano JI. Microstructure of the neocortex: comparative aspects. J Neurocytol. 2002; 31(3): 299-316.
9. Zhao S, Shetty J, Hou L, Delcher A, Zhu B, Osoegawa K, et al. Human, mouse and rat genome large-scale rearrangements: stability versus speciation. Genome Res. 2004; 14: 1851-60.
10. Gibbs RA, Rogers J, Katze MG, Bumgarner R, Weinstock GM, Mardis ER, et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science. 2007; 316(5822): 222-34.
11. Thomas H. Lessons from TGN1412. Lancet. 2006; 368(9547): 1569-70. doi: 10. 1016/s0140-6736(06)69651-7.
12. Barnes MR, Holbrook J, Feild JA, Searls DB, Sanseau P. Risk in drug trials. Lancet. 2006; 368(9554): 2205.
13. Dávalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke. 1997; 28(4): 708-10.
14. Williams SM, Sullivan RKP, Scott HL, Finkelstein DI, Colditz PB, Lingwood BE, et al. Glial glutamate transporter expression patterns in brains from multiple mammalian species. Glia. 2005; 49(4): 520-41. doi: 10. 1002/glia. 20139.
15. Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov. 2007; 6(8): 605-16.
16. Marcoli M, Bonfanti A, Roccatagliata P, Chiaramonte G, Ongini E, Raiteri M, et al. Glutamate efflux from human cerebrocortical slices during ischemia: vesicular-like mode of glutamate release and sensitivity to A2A adenosine receptor blockade. Neuropharmacology. 2004; 47(6): 884-91.
17. Werth JL, Park TS, Silbergeld DL, Rothman SM. Excitotoxic swelling occurs in oxygen and glucose deprived human cortical slices. Brain Res. 1998; 782(1-2): 248-54.
18. Römer PS, Berr S, Avota E, Na S-Y, Battaglia M, ten Berge I, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011; 118(26): 6772-82. doi: 10. 1182/blood-2010-12-319780.
19. Kaufman DS, Hanson ET, Lewis RL, Auerbach R. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA. 2001; 98(19): 1071-721.
20. The National Institutes of Health resource for stem cell research. Stem cell information http://stemcells. nih. gov. In: Stem cell information USA. 2012.
21. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011; 144(3): 439-52. doi: 10. 1016/j. cell. 2010. 12. 032.
22. Goldberg MP, Strasseer U, Dugan L. Techniques for assessing neuroprotective drugs in vitro. Int Rev Neurobiol. 1997; 40: 69-93.
23. Green AR, Cross AJ. Neuroprotective agents and cerebral ischaemia. London: Academic; 1997. London.
24. Howells DW, Sena ES, O'Collins V, Macleod MR. Improving the efficiency of the development of drugs for stroke. Int J Stroke. 2012; 7(5): 371-7.
25. Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). Lab Chip. 2012; 12(10): 1784-92.
26. Koroleva A, Gill AA, Ortega I, Haycock JW, Schlie S, Gittard SD, et al. Two-photon polymerisation-generated and micromolding-replicated 3D scaffolds for peripheral neural tissue engineering applications. Biofabrication. 2012; 4(2): 025005.